Skip to main content Back to Top
Advertisement

9/27/2016

Cefpodoxime

Products Affected - Description

    • Cefpodoxime oral suspension, Aurobindo, 100 mg/5 mL, 100 mL bottle, 1 count, NDC 65862-0141-01
    • Cefpodoxime oral suspension, Aurobindo, 100 mg/5 mL, 50 mL bottle, 1 count, NDC 65862-0141-50
    • Cefpodoxime oral suspension, Aurobindo, 50 mg/5 mL, 100 mL bottle, 1 count, NDC 65862-0140-01
    • Cefpodoxime oral suspension, Aurobindo, 50 mg/5 mL, 50 mL bottle, 1 count, NDC 65862-0140-50
    • Cefpodoxime oral suspension, Sandoz, 100 mg/5 mL, 50 mL bottle, 1 count, NDC 00781-6169-52
    • Cefpodoxime oral suspension, Sandoz, 50 mg/5 mL, 100 mL bottle, 1 count, NDC 00781-6168-46
    • Cefpodoxime oral suspension, Sandoz, 50 mg/5 mL, 50 mL bottle, 1 count, NDC 00781-6168-52

Reason for the Shortage

    • Aurobindo discontinued cefpodoxime oral suspension.
    • Pfizer has discontinued Vantin.
    • Ranbaxy has an import ban on all solid medications including cefpodoxime.
    • Sandoz could not provide a reason for the shortage. They have discontinued 50 mg/mL 50 mL and 100 mL oral suspension and 100 mg/mL 50 mL oral suspension.

Available Products

    • Cefpodoxime oral tablet, Aurobindo, 100 mg, 20 count, NDC 65862-0095-20
    • Cefpodoxime oral tablet, Aurobindo, 200 mg, 20 count, NDC 65862-0096-20
    • Cefpodoxime oral suspension, Sandoz, 100 mg/5 mL, 100 mL bottle, 1 count, NDC 00781-6169-46
    • Cefpodoxime oral tablet, Sandoz, 100 mg, 20 count, NDC 00781-5438-20
    • Cefpodoxime oral tablet, Sandoz, 200 mg, 20 count, NDC 00781-5439-20
    • Cefpodoxime oral tablet, Sandoz, 200 mg, 100 count, NDC 00781-5439-01

Estimated Resupply Dates

    • All marketed presentations are available.

Updated

Updated September 27, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. Created May 20, 2011 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.